Your session is about to expire
← Back to Search
NB-UVB vs PUVA for Hand Eczema/Psoriasis
Study Summary
This trial is testing whether a new treatment, narrow band ultraviolet B (NB-UVB) is better than the current standard treatment, psoralen with long wavelength ultraviolet A radiation (PUVA), for hand psoriasis/eczema.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have severe hand psoriasis or eczema on both hands, even after using creams.I am 18 years old or older.I am 18 years old or older.I don't have any serious illnesses that would prevent me from receiving light treatments.I haven't treated my hand psoriasis/eczema with creams for 2 weeks or with pills/light therapy for 4 weeks.I have severe, almost equal psoriasis or eczema on both hands.I have a condition that makes my skin unusually sensitive to sunlight.I have severe hand psoriasis or eczema on both hands.
- Group 1: Topical PUVA
- Group 2: NB-UVB
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is enrollment for this experiment open at the present time?
"The evidence on clinicaltrials.gov reveals that this trial is not actively recruiting participants, having last been updated in June 2015 after being posted back in February 2013. However, there are currently 79 other trials which require enrolment at this time."
Has the FDA sanctioned NB-UVB for medical use?
"Considering the Phase 2 standing of NB-UVB, our team at Power has assigned it a safety rating of 2. This designation is due to there being evidence indicating its security but still no proof regarding effectiveness."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger